Title

Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013

Creator(s)

Daniel C. Payne, National Center for Immunization and Respiratory Diseases
Rangaraj Selvarangan, Children's Mercy HospitalFollow
Parvin H. Azimi, UCSF Benioff Children's Hospital Oakland
Julie A. Boom, Texas Children's Hospital
Janet A. Englund, Seattle Children's Hospital
Mary Allen Staat, Cincinnati Children's Hospital Medical Center
Natasha B. Halasa, Vanderbilt University Medical Center
Geoffrey A. Weinberg, University of Rochester
Peter G. Szilagyi, University of Rochester
James Chappell, Vanderbilt University Medical Center
Monica McNeal, Cincinnati Children's Hospital Medical Center
Eileen J. Klein, Seattle Children's Hospital
Leila C. Sahni, Texas Children's Hospital
Samantha H. Johnston, UCSF Benioff Children's Hospital Oakland
Christopher J. Harrison, Children's Mercy HospitalFollow
Carol J. Baker, Baylor College of Medicine
David I. Bernstein, Cincinnati Children's Hospital Medical Center
Mary Moffatt, Children's Mercy HospitalFollow
Jacqueline E. Tate, National Center for Immunization and Respiratory Diseases
Slavica Mijatovic-Rustempasic, National Center for Immunization and Respiratory Diseases
Mathew D. Esona, National Center for Immunization and Respiratory Diseases
Mary E. E. Wikswo, National Center for Immunization and Respiratory Diseases
Aaron T. Curns, National Center for Immunization and Respiratory Diseases
Iddrisu Sulemana, National Center for Immunization and Respiratory Diseases
Michael D. Bowen, National Center for Immunization and Respiratory Diseases
Jon R. Gentsch, National Center for Immunization and Respiratory Diseases
Umesh D. Parashar, National Center for Immunization and Respiratory Diseases

Document Type

Article

Publication Date

12-15-2015

Identifier

DOI: 10.1093/cid/civ872

Abstract

© 2015 Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Background. Using a multicenter, active surveillance network from 2 rotavirus seasons (2012 and 2013), we assessed the vaccine effectiveness of RV5 (RotaTeq) and RV1 (Rotarix) rotavirus vaccines in preventing rotavirus gastroenteritis hospitalizations and emergency department (ED) visits for numerous demographic and secular strata.

Methods. We enrolled children hospitalized or visiting the ED with acute gastroenteritis (AGE) for the 2012 and 2013 seasons at 7 medical institutions. Stool specimens were tested for rotavirus by enzyme immunoassay and genotyped, and rotavirus vaccination histories were compared for rotavirus-positive cases and rotavirus-negative AGE controls. We calculated the vaccine effectiveness (VE) for preventing rotavirus associated hospitalizations and ED visits for each vaccine, stratified by vaccine dose, season, clinical setting, age, predominant genotype, and ethnicity.

Results. RV5-specific VE analyses included 2961 subjects, 402 rotavirus cases (14%) and 2559 rotavirus-negative AGE controls. RV1-specific VE analyses included 904 subjects, 100 rotavirus cases (11%), and 804 rotavirus-negative AGE controls. Over the 2 rotavirus seasons, the VE for a complete 3-dose vaccination with RV5 was 80% (confidence interval [CI], 74%-84%), and VE for a complete 2-dose vaccination with RV1 was 80% (CI, 68%-88%). Statistically significant VE was observed for each year of life for which sufficient data allowed analysis (7 years for RV5 and 3 years for RV1). Both vaccines provided statistically significant genotype-specific protection against predominant circulating rotavirus strains.

Conclusions. In this large, geographically and demographically diverse sample of US children, we observed that RV5 and RV1 rotavirus vaccines each provided a lasting and broadly heterologous protection against rotavirus gastroenteritis.

Journal Title

Clinical Infectious Diseases

Volume

61

Issue

12

First Page

1792

Last Page

1799

Keywords

acute gastroenteritis, rotavirus vaccine, RV1-Rotarix, RV5-RotaTeq, surveillance

Share

COinS